All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Should we use melflufen to treat relapsed patients with poor prognosis?
Bookmark this article
Video series
ASH 2020 | Novel therapies for RRMM
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Paul G. Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, Should we use melflufen to treat relapsed patients with poor prognosis?
Richardson discusses promising data from the HORIZON trial evaluating melflufen, a highly lipophilic peptide-drug conjugate, in patients with relapsed/refractory myeloma. Richardson then discusses preliminary data from the ANCHOR study, evaluating melflufen in combination with dexamethasone, and either daratumumab or bortezomib, in patients with relapsed/refractory myeloma.
Video series
ASH 2020 | Novel therapies for RRMM
Your opinion matters
60 votes - 52 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox